|
Poveda-Garcia A, Ruiz E, Moreno MJ, Espanol I, Sanchez-Salinas A, Garcia-Hernandez AM, Blanquer M, Martinez I, Sanchez-Villalobos M, Garcia Garay MC, Salido E, Heredia A, Navarro-Almenzar B, Monserrat J, Sanchez-Salas JA, Martinez-Mellado AJ, Minguela A, Campillo JA, Lopez-Hernandez R, Galian JA, Moraleda JM, Roldan V, Cabanas V. Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis. Bone Marrow Transplant. 2024 Nov;59(11):1625-1627. doi: 10.1038/s41409-024-02404-1. Epub 2024 Aug 26. No abstract available. PubMed PMID: 39187602.
AÑO: 2024; IF: 4.5
|
39187602
|
Torregrosa JM, Ferrer-Marín F, Lozano ML, Moreno MJ, Martinez C, Anton AI, Rivera J, Vicente V. Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation. Br J Haematol. 2016 Mar;172(5):813-5. doi: 10.1111/bjh.13539. Epub 2015 Jun 30. PubMed PMID: 26132594.
AÑO: 2016; IF: 5.67
|
|
Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, Brunet S, Tormo M, Fernández-Abellán P, Guàrdia R, Bernal MT, Esteve J, Barba P, Moreno MJ, Bermúdez A, Cladera A, Escoda L, García-Boyero R, Del Potro E, Bergua J, Amigo ML, Grande C, Rabuñal MJ, Hernández-Rivas JM, Feliu E. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014 May 20;32(15):1595-604. doi: 10.1200/JCO.2013.52.2425. PubMed PMID: 24752047.
AÑO: 2014; IF: 18.443
|
|
Titos-Arcos JC, León-Villar J, de Arriba de la Fuente F, Moreno Belmonte MJ, Iranzo Fernández MD. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital]. Farm Hosp. 2012 Jul-Aug;36(4):275-81. Spanish. PubMed PMID: 22115856.
AÑO: 2012
|
|
Oriol A, Vives S, Hernández-Rivas JM, Tormo M, Heras I, Rivas C, Bethencourt C, Moscardó F, Bueno J, Grande C, del Potro E, Guardia R, Brunet S, Bergua J, Bernal T, Moreno MJ, Calvo C, Bastida P, Feliu E, Ribera JM; Programa Español de Tratamiento en Hematologia Group. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010 Apr;95(4):589-96. doi: 10.3324/haematol.2009.014274. Epub 2010 Feb 9. PubMed PMID: 20145276; PubMed Central PMCID: PMC2857188.
AÑO: 2010; IF: 6.532
|